ZIMMER BIOMET HOLDINGS, INC. Financials Zimmer Biomet Holdings, Inc.
Equities
ZBH
US98956P1021
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 120.3 USD | -0.90% |
|
+0.64% | -1.13% |
| May. 03 | Raymond James Adjusts Price Target on Zimmer Biomet Holdings to $138 From $142 | MT |
| May. 03 | UBS Adjusts Price Target on Zimmer Biomet Holdings to $112 From $109, Maintains Sell Rating | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 30,787 | 31,940 | 26,540 | 26,756 | 25,433 | 24,982 | - | - |
| Enterprise Value (EV) 1 | 38,390 | 39,264 | 33,130 | 32,077 | 30,785 | 29,213 | 27,731 | 27,189 |
| P/E ratio | 27.4 x | -230 x | 66.5 x | 116 x | 24.9 x | 25 x | 21.3 x | 18.5 x |
| Yield | 0.64% | 0.62% | 0.76% | 0.75% | 0.79% | 0.83% | 0.86% | 0.86% |
| Capitalization / Revenue | 3.86 x | 4.55 x | 3.39 x | 3.86 x | 3.44 x | 3.22 x | 3.08 x | 2.96 x |
| EV / Revenue | 4.81 x | 5.59 x | 4.23 x | 4.62 x | 4.16 x | 3.77 x | 3.42 x | 3.22 x |
| EV / EBITDA | 14.7 x | 19.2 x | 13.3 x | 14 x | 12.4 x | 10.9 x | 9.8 x | 9.8 x |
| EV / FCF | 36.1 x | 49.4 x | 32.3 x | 35.2 x | 31.5 x | 27.6 x | 18.2 x | 16.9 x |
| FCF Yield | 2.77% | 2.03% | 3.1% | 2.84% | 3.18% | 3.63% | 5.51% | 5.93% |
| Price to Book | 2.49 x | 2.62 x | 2.1 x | 2.22 x | 2 x | 1.82 x | 1.63 x | 1.51 x |
| Nbr of stocks (in thousands) | 205,684 | 207,278 | 208,909 | 209,852 | 208,981 | 205,728 | - | - |
| Reference price 2 | 149.7 | 154.1 | 127.0 | 127.5 | 121.7 | 121.4 | 121.4 | 121.4 |
| Announcement Date | 2/4/20 | 2/5/21 | 2/7/22 | 2/3/23 | 2/8/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7,982 | 7,024 | 7,836 | 6,940 | 7,394 | 7,752 | 8,113 | 8,443 |
| EBITDA 1 | 2,610 | 2,044 | 2,487 | 2,293 | 2,477 | 2,676 | 2,830 | 2,775 |
| EBIT 1 | 2,188 | 1,609 | 2,035 | 1,894 | 2,087 | 2,246 | 2,383 | 2,513 |
| Operating Margin | 27.42% | 22.91% | 25.97% | 27.29% | 28.22% | 28.97% | 29.37% | 29.76% |
| Earnings before Tax (EBT) 1 | 905.8 | -274.4 | 418.4 | 403.5 | 1,067 | 1,207 | 1,470 | - |
| Net income 1 | 1,132 | -138.9 | 401.6 | 231.4 | 1,024 | 1,044 | 1,239 | 1,392 |
| Net margin | 14.18% | -1.98% | 5.12% | 3.33% | 13.85% | 13.46% | 15.27% | 16.49% |
| EPS 2 | 5.470 | -0.6700 | 1.910 | 1.100 | 4.880 | 4.866 | 5.701 | 6.564 |
| Free Cash Flow 1 | 1,063 | 795.3 | 1,025 | 910 | 978.8 | 1,059 | 1,528 | 1,612 |
| FCF margin | 13.31% | 11.32% | 13.09% | 13.11% | 13.24% | 13.66% | 18.83% | 19.09% |
| FCF Conversion (EBITDA) | 40.72% | 38.91% | 41.23% | 39.68% | 39.51% | 39.59% | 53.98% | 58.09% |
| FCF Conversion (Net income) | 93.92% | - | 255.33% | 393.26% | 95.59% | 101.5% | 123.27% | 115.8% |
| Dividend per Share 2 | 0.9600 | 0.9600 | 0.9600 | 0.9600 | 0.9600 | 1.011 | 1.047 | 1.050 |
| Announcement Date | 2/4/20 | 2/5/21 | 2/7/22 | 2/3/23 | 2/8/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,038 | 1,663 | 1,782 | 1,670 | 1,825 | 1,831 | 1,870 | 1,754 | 1,940 | 1,889 | 1,941 | 1,864 | 2,066 | 1,977 | 2,034 |
| EBITDA 1 | 642.2 | 542.2 | 597.9 | 748 | 613.9 | 618.7 | 613.6 | 560 | 684.8 | 635.9 | 658.7 | 623.3 | 734.9 | 673.3 | 707.3 |
| EBIT 1 | 527 | 439.2 | 498.2 | 439.5 | 516.9 | 520.3 | 514.3 | 463.8 | 588.5 | 539.4 | 553.6 | 523.2 | 630 | 567.4 | 588.7 |
| Operating Margin | 25.86% | 26.41% | 27.96% | 26.32% | 28.32% | 28.42% | 27.51% | 26.45% | 30.33% | 28.55% | 28.52% | 28.07% | 30.5% | 28.7% | 28.94% |
| Earnings before Tax (EBT) 1 | -138.7 | 101.2 | 199.5 | 478.3 | -74.8 | 286.8 | 276.8 | 219.2 | 284.4 | 215.1 | 317.5 | 280.8 | 393.7 | 316.8 | 374.3 |
| Net income 1 | -84 | 14.2 | 153.7 | 361.9 | -130.5 | 232.5 | 209.6 | 162.7 | 419.2 | 172.4 | 264.5 | 233.8 | 345.2 | 293.1 | 312.2 |
| Net margin | -4.12% | 0.85% | 8.63% | 21.67% | -7.15% | 12.7% | 11.21% | 9.28% | 21.61% | 9.13% | 13.63% | 12.54% | 16.71% | 14.82% | 15.35% |
| EPS 2 | -0.4000 | 0.0700 | 0.7300 | 1.720 | -0.6200 | 1.110 | 1.000 | 0.7700 | 2.010 | 0.8400 | 1.250 | 1.144 | 1.567 | 1.340 | 1.488 |
| Dividend per Share 2 | 0.2400 | 0.2400 | 0.2400 | 0.2400 | 0.2400 | 0.2400 | 0.2400 | - | 0.2400 | - | 0.2436 | 0.2431 | 0.2432 | 0.2491 | 0.2488 |
| Announcement Date | 2/7/22 | 5/3/22 | 8/2/22 | 11/2/22 | 2/3/23 | 5/2/23 | 8/1/23 | 11/7/23 | 2/8/24 | 5/2/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 7,604 | 7,324 | 6,590 | 5,321 | 5,352 | 4,232 | 2,750 | 2,207 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.913 x | 3.583 x | 2.65 x | 2.32 x | 2.161 x | 1.581 x | 0.9717 x | 0.7954 x |
| Free Cash Flow 1 | 1,063 | 795 | 1,025 | 910 | 979 | 1,059 | 1,528 | 1,612 |
| ROE (net income / shareholders' equity) | 13.7% | 9.61% | 12.5% | 11.7% | 12.9% | 13% | 12.9% | 15.2% |
| ROA (Net income/ Total Assets) | 6.67% | 4.82% | 6.48% | 6.51% | 7.44% | 7.72% | 8.23% | 12.8% |
| Assets 1 | 16,965 | -2,883 | 6,202 | 3,555 | 13,756 | 13,514 | 15,056 | 10,878 |
| Book Value Per Share 2 | 60.10 | 58.70 | 60.60 | 57.50 | 60.70 | 66.90 | 74.50 | 80.40 |
| Cash Flow per Share 2 | 7.670 | 5.820 | 7.130 | 6.450 | 7.540 | 9.930 | 11.20 | 14.10 |
| Capex 1 | 523 | 409 | 474 | 446 | 603 | 581 | 603 | 625 |
| Capex / Sales | 6.55% | 5.83% | 6.05% | 6.43% | 8.15% | 7.5% | 7.43% | 7.4% |
| Announcement Date | 2/4/20 | 2/5/21 | 2/7/22 | 2/3/23 | 2/8/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
121.4
USD
Average target price
136.6
USD
Spread / Average Target
+12.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.22% | 24.98B | |
| -3.54% | 185B | |
| -0.58% | 109B | |
| -2.74% | 68.54B | |
| +4.84% | 51.74B | |
| +10.40% | 45.22B | |
| +3.12% | 41.74B | |
| +2.87% | 26.69B | |
| +4.61% | 26.83B | |
| +11.62% | 25.63B |
- Stock Market
- Equities
- ZBH Stock
- Financials Zimmer Biomet Holdings, Inc.